Dr Anne Peters discusses updates in the ADA 2026 Standards of Care in Diabetes, focusing on the use of technology.

Abbott shares fell after quarterly sales and early 2026 earnings guidance missed estimates, even as the company forecast ...

Abbott missed analysts’ profit expectations for Q4 2025, yet the company’s full year financials were buoyed by strong ...

Despite facing headwinds, Abbott Laboratories (ABT) reports robust earnings growth and outlines plans for innovation and ...

Abbott Laboratories and Abbott Diabetes Care were hit with a consumer class action on Jan. 1 in California Northern District Court over allegedly defective continuous glucose monitoring sensors. The ...

The "Blood Ketone Meter Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ResearchAndMarkets.com's offering. The Global Blood Ketone Meter Market is ...

Abbott Diabetes Care and Abbott Laboratories were hit with a consumer class action on Jan. 1 in California Northern District Court over allegedly defective FreeStyle Libre 3 continuous glucose ...

Abbott Laboratories (NYSE:ABT) Q4 2025 Earnings Call Transcript January 22, 2026 Abbott Laboratories reports earnings inline ...

The mixed earnings report comes on the heels of the Abbott Park, IL-based company announcing it would acquire Exact Sciences for $21 billion.

Abbott’s (NYSE: ABT) newest sensor-based glucose technology, the FreeStyle Libre 3 Plus* sensor, is now publicly funded in every province across ...

Abbott's revenue has been flat over 15 months with steady Q3 EPS of $1.30, 7% growth, and upcoming Q4 international segment ...

Libre Assist 1 uses generative AI to predict how a food choice may affect a person's glucose levels. 2 It then offers actionable and personalized meal guidance 3 to support in-the-moment decisions.